Overslaan en naar de inhoud gaan

 Alle verbonden artikelen

Minimal residual disease and circulating tumor cells in breast cancer: open questions for research.

Auteurs : Ignatiadis M, Sotiriou C, Pantel K
Jaar : 2012
Journal : Recent Results Cancer Res.
Volume : 195
Pagina's : 3-9

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Auteurs : Awada A, Bozovic-Spasojevic I, Chow L
Jaar : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pagina's : 494-504

Clinical trial design in head and neck cancer: from past experiences to future perspectives.

Auteurs : de Castro G Jr, Henrique dos Anjos C, Lalami Y, Awada A
Jaar : 2012
Journal : Clinical Investigation
Volume : 2(5)
Pagina's : 473-481

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

Auteurs : Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G
Jaar : 2012
Journal : Breast
Volume : 21(1)
Pagina's : 20-6

Understanding the biology of triple-negative breast cancer.

Auteurs : Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C
Jaar : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pagina's : vi13-vi18

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Auteurs : Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart-Gebhart M, Harbeck N
Jaar : 2012
Journal : Breast Cancer Res. Treat.
Volume : 134(3)
Pagina's : 1149-59

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Auteurs : Berghmans T, Remmelink M, Awada A
Jaar : 2012
Journal : Lung Cancer : Targets and Therapy
Volume : 3
Pagina's : 91-99

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Auteurs : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Jaar : 2012
Journal : Ann Oncol
Volume : 23
Pagina's : 2997-3006

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Auteurs : Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L
Jaar : 2012
Journal : Breast
Volume : 21(4)
Pagina's : 507-13

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.

Auteurs : Azim H, Azim HA
Jaar : 2012
Journal : Future Oncol
Volume : 8(2)
Pagina's : 135-44

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Auteurs : Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart-Gebhart M
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(6)
Pagina's : e240-8

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

Auteurs : Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T, Uhl W, Van Tienhoven G, Bachet JB, Maréchal R, Hendlisz A, Bali M, Demetter P, Ulrich F, Aust D, Luttges J, Peeters M, Mauer M, Roth A, Neoptolemos JP, Lutz M
Jaar : 2012
Journal : Ann Oncol
Volume : 23
Pagina's : 570-576

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Auteurs : Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(9)
Pagina's : 897-905

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.

Auteurs : Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber Rd, Bernhard J, + collaborators (among others :, Nogaret JM
Jaar : 2012
Journal : Br J Cancer
Volume : 106(10)
Pagina's : 1618-25

The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study.

Auteurs : Azim HA, Botteri E, Renne G, Dell orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart-Gebhart M, Goldhirsch A, Viale G, Peccatori F
Jaar : 2012
Journal : Acta oncol (Stockholm)
Volume : 51(5)
Pagina's : 653-61

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

Auteurs : Ignatiadis M, Piccart-Gebhart M
Jaar : 2012
Journal : Ann Oncol
Volume : 23(7)
Pagina's : 1653-5

Pemetrexed salvage chemotherapy for NSCLC: implementation study].

Auteurs : Jungels C, Berghmans T, Meert AP, Lafitte JJ, Scherpereel A, Sculier JP
Jaar : 2012
Journal : Rev Mal Respir
Volume : 29(1)
Pagina's : 21-7

Are there several kinds of palliative care?

Auteurs : Klastersky J
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(4)
Pagina's : 355-6

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Auteurs : Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, Mcgale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart-Gebhart M, Pritchard K
Jaar : 2012
Journal : Lancet
Volume : 379(9814)
Pagina's : 432-44

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

Auteurs : Bleiberg H, Vandebroek A, Deleu I, Vergauwe P, Rezaei Kalantari H, DHaens G, Paesmans M, Peeters M, Efira A, Humblet Y
Jaar : 2012
Journal : Acta Gastroenterol Belg
Volume : 75(1)
Pagina's : 14-21